Nam Joo Yeon, de Groot John F
The University of Texas MD Anderson Cancer Center, Houston, TX.
J Oncol Pract. 2017 Oct;13(10):629-638. doi: 10.1200/JOP.2017.025536.
Glioblastoma is the most common and most aggressive form of primary brain tumor in adults and contributes to high social and medical burden as a result of its incurable nature and significant neurologic morbidity. Despite ongoing research, there has not been improvement in survival in glioblastoma. This review discusses recent advances in clinically significant molecular profiling, including IDH mutation status and O-methylguanine-DNA methyltransferase ( MGMT) promoter methylation. We review updates in management of newly diagnosed and recurrent glioblastoma, as well as common difficulties in management, such as pseudoprogression and pseudoresponse. Ongoing translational research in targeted therapy and immunotherapy is briefly discussed.
胶质母细胞瘤是成人原发性脑肿瘤中最常见且侵袭性最强的类型，由于其无法治愈的特性和严重的神经功能障碍，造成了巨大的社会和医疗负担。尽管研究不断，但胶质母细胞瘤患者的生存率并未得到改善。本综述讨论了临床意义重大的分子谱分析的最新进展，包括异柠檬酸脱氢酶（IDH）突变状态和O-甲基鸟嘌呤-DNA甲基转移酶（MGMT）启动子甲基化。我们回顾了新诊断和复发性胶质母细胞瘤治疗的最新进展，以及治疗中常见的困难，如假性进展和假性反应。还简要讨论了靶向治疗和免疫治疗方面正在进行的转化研究。
